FDA Inspection 1065837 — Adam S. Giermasz, M.D., Ph.D.
The FDA completed an inspection of Adam S. Giermasz, M.D., Ph.D. on August 16, 2018 in Sacramento, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- August 16, 2018
- Fiscal Year
- 2018
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Sacramento, CA (United States)
Additional Details
Clinical Investigator (CI)